Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval
Conditional Approval In Store For The Lymphoma Treatment
Executive Summary
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
You may also be interested in...
EU: Rigel And Jazz Among Hopefuls At CHMP
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
EU: Stakes High For Novartis At Latest CHMP Meeting
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.
Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
